SAR447189 / Teva, Sanofi  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
SAR447189 / Teva, Sanofi
NCT04545385: A Study to Test if TEV-48574 is Effective in Relieving Asthma

Terminated
2
65
Europe, US, RoW
TEV-48574, Placebo
Teva Branded Pharmaceutical Products R&D, Inc.
Asthma
01/22
01/22
2020-001927-15: A Study to Test if TEV-48574 is Effective in Relieving Asthma

Not yet recruiting
2
124
Europe, RoW
TEV-48574, TEV-48574, Solution for injection
Teva Branded Pharmaceutical Products R&D, Inc., Teva Branded Pharmaceutical Products R&D, Inc.
T2-low/non-T2 Severe Uncontrolled Asthma, Asthma, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
RELIEVE UCCD, NCT05499130 / 2021-006881-19: A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease

Recruiting
2
240
Europe, Canada, Japan, US, RoW
TEV-48574, Placebo
Teva Branded Pharmaceutical Products R&D, Inc., Teva Branded Pharmaceutical Products R&D, Inc.
Crohn Disease, Colitis, Ulcerative
12/24
01/25
NCT05668013 / 2022-002593-89: A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease

Recruiting
2
218
Europe, Japan, US, RoW
TEV-48574 Dose Regimen A, TEV-48574 Dose Regiment B
Teva Branded Pharmaceutical Products R&D, Inc., Sanofi
Crohn Disease, Colitis, Ulcerative
07/31
08/31

Download Options